Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R P Baum

Showing results (111-120 of 136) with videos related to

Pageof 14
Sort By:
Leukemia & Lymphoma|September 24, 1999
Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's diseaseE Wiedmann, B Baican, A Hertel, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 5, 1998
[Value of 18F fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumors]A N Rahn, R P Baum, I A Adamietz, et al.
Revista Espanola De Medicina Nuclear|April 10, 2002
[Pilot study with the monoclonal antibody IOR-C5 as a potential agent of radioimmunoscintigraphy in colorectal cancer]J P Oliva, G Pimentel, M Borrón, et al.
European Journal of Pediatrics|May 1, 1987
131-Metaiodobenzylguanedine therapy of neuroblastoma in childhood. One year of therapeutic experienceD Schwabe, S Sahm, V Gerein, et al.
Revista Espanola De Medicina Nuclear|March 12, 1999
[Radioimmunoscintigraphy of colorectal cancer using the anti-CEA monoclonal antibody BW 431/26. Final results]J Oliva, G Pimentel, R Peralta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1996
Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECTI A Adamietz, R P Baum, F Schemman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1996
Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulationM Eisenhut, W D Lehmann, W Becker, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1993
A novel technetium-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECTR P Baum, S Adams, J Kiefer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2015
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumorsL Bodei, M Kidd, I M Modlin, et al.
Cancer|February 1, 1994
Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinomaR P Baum, A Niesen, A Hertel, et al.
Pageof 14

Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
Leukemia & Lymphoma|September 24, 1999
Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's diseaseE Wiedmann, B Baican, A Hertel, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 5, 1998
[Value of 18F fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumors]A N Rahn, R P Baum, I A Adamietz, et al.
Revista Espanola De Medicina Nuclear|April 10, 2002
[Pilot study with the monoclonal antibody IOR-C5 as a potential agent of radioimmunoscintigraphy in colorectal cancer]J P Oliva, G Pimentel, M Borrón, et al.
European Journal of Pediatrics|May 1, 1987
131-Metaiodobenzylguanedine therapy of neuroblastoma in childhood. One year of therapeutic experienceD Schwabe, S Sahm, V Gerein, et al.
Revista Espanola De Medicina Nuclear|March 12, 1999
[Radioimmunoscintigraphy of colorectal cancer using the anti-CEA monoclonal antibody BW 431/26. Final results]J Oliva, G Pimentel, R Peralta, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1996
Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECTI A Adamietz, R P Baum, F Schemman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1996
Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulationM Eisenhut, W D Lehmann, W Becker, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1993
A novel technetium-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECTR P Baum, S Adams, J Kiefer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2015
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumorsL Bodei, M Kidd, I M Modlin, et al.
Cancer|February 1, 1994
Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinomaR P Baum, A Niesen, A Hertel, et al.
Pageof 14